BCM
SBFM

Bridgeway Capital Management’s Sunshine Biopharma SBFM Stock Holding History

Bridgeway Capital Management’s Portfolio SBFM Stock Details SBFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-14
Closed -$17.3K – 1335
2024
Q1 		$17.3K Hold
14
– – ﹤0.01% 1294
2023
Q4 		$77.7K Hold
14
– – ﹤0.01% 1277
2023
Q3 		$89K Hold
14
– – ﹤0.01% 1247
2023
Q2 		$141K Hold
14
– – ﹤0.01% 1202
2023
Q1 		$200K Hold
14
– – 0.01% 1105
2022
Q4 		$183K Hold
14
– – ﹤0.01% 1104
2022
Q3 		$221K Sell
14
-14
-50% -$304K 0.01% 1120
2022
Q2 		$614K Buy
+28
New +$1.37M 0.01% 835

Other funds holding SBFM

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
MSG
Main Street Group Glen Allen, Virginia $429M AUM 34.03% 1-Year Est. Return

Bridgeway Capital Management's SBFM Position: Q2 2024 in Review

Bridgeway Capital Management sold out of Sunshine Biopharma (SBFM) in Q2 2024, closing a stake of 14 shares — an estimated $17.3K sold.

Bridgeway Capital Management first reported a position in SBFM in Q2 2022 and held it in 8 quarters. The position peaked at $614K in Q2 2022. 8 funds tracked by Wall St. Rank hold SBFM as of Q2 2024.

  • Bridgeway Capital Management reported no remaining Sunshine Biopharma position as of Q2 2024 after selling out during the quarter.
  • Bridgeway Capital Management sold 14 Sunshine Biopharma shares in Q2 2024, an estimated $17.3K.
  • Bridgeway Capital Management first reported a position in Sunshine Biopharma in Q2 2022 and held it in 8 quarters.
  • Bridgeway Capital Management's Sunshine Biopharma position peaked at $614K in Q2 2022.
  • 8 funds tracked by Wall St. Rank held Sunshine Biopharma as of Q2 2024.

Based on Bridgeway Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.